medigraphic.com
ISSN 0210-5187 (Digital)

2004, Número 3

<< Anterior Siguiente >>

Med Cutan Iber Lat Am 2004; 32 (3)


Manifestações cutâneas da síndrome dos ovários policísticos. Fisiopatologia, diagnóstico e tratamento

Carvalho LJ A, Carvalho LA

Idioma: Portugués
Referencias bibliográficas: 67
Paginas: 93-99
Archivo PDF: 177.47 Kb.


FRAGMENTO

No abstract


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Lobo R, Carmina E. The Importance of Diagnosing the Polycystic Ovary Syndrome. Ann Intern Med 2000; 132: 989-93.

  2. Trent ME, Rich M, Austin SB, Gordon CM. Quality of life in Adolescent Girls with Polycystic Ovary Syndrome. Arch Pediatr Adolesc Med 2002; 156: 556-60.

  3. Taylor AE. Insulin-Lowering Medications in Polycystic Ovary Syndrome. Obstet Gynecol Clin 2000; 27: 583-95.

  4. Baillargeon JP, Iuorno MJ, Nestler JE, et al. Insulin Sensitizers for Polycystic Ovary Syndrome. Clin Obstet Gynaecol 2003; 46:325-40.

  5. Meirelles RMR. Desvendando os Mistérios da Mulher (pelo Menos os Endócrinos). Arq Bras Endocrinol Metab 2001; 45:317-9.

  6. Tartagni M, Schonauer LM, De Salvia MA, et al. Comparison of Diane 35 and Diane 35 plus finasteride in the treatment of hirsutism. Fertil Steril 2000; 73: 718-23.

  7. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al. Survey of the Polycystic Ovary Syndrome in the Greek Island of Lesbos: Hormonal and Metabolic Profile. J Clin Endocrinol Metab 1999; 84: 4006-11.

  8. Kovacs GT. Polycystic Ovary Syndrome. Cambridge University Press, 2000,UK.

  9. Jonard S, Robert Y, Cortet-Rudelli C, Pigny P, Decanter C, Dewailly D. Ultrasound examination of polycystic ovaries: is it worth counting the follicles? Hum Reprod 2003; 18: 598-603.

  10. Shaw JC. Hormonal therapy in Dermatology. Dermatol Clin 2001; 19: 169-78.

  11. Meisler JG. Toward Optimal Health: The Experts Discuss Facial Skin and Related Concerns in Women. J Women Health 2003; 12: 533-9.

  12. Sttaford DEJ, Gordon CM. Adolescents androgen abnormalities. Curr Opin Obstet Gynecol 2002; 14: 445-51.

  13. Pastor CL, Griffin-Korf ML, Aloi JA, et al. Polycystic Ovary Syndrome: Evidence for Reduced Sensitivity of the Gonadotropin-Releasing Hormone Pulse Generator to Inhibition by Estradiol and Progesterone. J Clin Endocrinol Metab 1998; 83: 251-62.

  14. Lobo RA. Role of the adrenal in polycystic ovary syndrome. Semin Reprod Endocrinol 1984; 2: 251-62.

  15. De Leo V, La Marca A, Petraglia F. Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome. Endocr Rev 2003; 24: 633-67.

  16. Nelson VL, Qin K, Rosenfield RL, et al. The Biochemical Basis for Increased Testosterone Production in Theca Cells Propagated from Patients with Polycystic Ovary Syndrome. J Clin Endocrinol Metab 2001; 86: 5925-33.

  17. Franks S. Polycystic ovary syndrome. N Engl J Med 1995; 333: 853-61.

  18. Xita N, Georgiou I, Tsatsoulis A. The genetic basis of polycystic ovary syndrome. Eur J Endocrinol 2002; 147: 717-25.

  19. Jayagopal V, Kilpatrick ES, Holding S, et al. The Biological Variation of Insulin Resistance in Polycystic Ovarian Syndrome. J Clin Endocrinol Metab 2002; 87: 1560-2.

  20. Harris GS, Kozarich JW. Steroid 5α-reductase inhibitors in androgen-dependent disorders. Curr Opin Chem Biol 1997; 1:254-9.

  21. Springer K, Brown M, Stulberg DL. Common Hair Disorders. Am Fam Physician 2003; 68:107-8.

  22. Dunaif A. Insulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implications for Pathogenesis. Endocr Rev 1997; 18: 774-800.

  23. Hachanefioglu B, Mamhmutoglu I, Sercelik A, et al. Hyperandrogenism: Effect of hypertension therapy with the angiotensin-converting enzyme inhibitor lisinopril on hyperandrogenism in women with polycystic ovary syndrome. Fertil Steril 2002; 77: 526-8.

  24. Nacul A, Comim F, Spritzel PM. Aspectos Neuroendócrinos na Síndrome dos Ovários Policísticos. Arq Bras Endocrinol Metab 2003; 47: 432-9.

  25. Norman RJ, Wu R, Stankiewicz MT. Polycystic Ovary Syndrome. MJA 2004; 180: 132-7.

  26. Franks S. Polycystic ovary syndrome: a changing perspective. Clin Endocrinol 1989; 31: 87-120.

  27. Yen SSC. The Polycystic Ovary syndrome. Clin Endocrinol (Oxf) 1980; 12: 177-207.

  28. Doldi N, Marsiglio E, Destefani A, et al. Polycystic ovary syndrome: anomalies in progesterone Production. Human Reprod 1998; 13: 290-3.

  29. Mitwally MF, Casper RF. Aromatase inhibition for ovarian stimulation: future avenues for infertility management. Curr Opin Obstet Gynecol 2002; 14: 255-63.

  30. Gordon CM. Menstrual disorders in adolescents. Excess androgens and the polycystic ovary syndrome. Pediatr Clin North Am 1999; 46: 519-43.

  31. Fassnatch, Martin, et al. Beyond Adrenal and Ovarian Androgen Generation: Increased Peripheral 5alpha-Reductase Activity in Women with Polycystic Ovary Syndrome. J Clin Endocrinol Metab 2003; 88: 2760-6.

  32. Sir-Petermann T, Angel B, Maliqueo M, et al. Prevalence of type II Diabetes mellitus and Insulin Resistance in parents of women with Polycystic Ovary Syndrome. Diabetol 2002; 45: 459-64.

  33. Rittmaster RS, Deshwal N, Lehman L, et al. The Role of Adrenal Hyperandrogenism, Insulin Resistance, and Obesity in the Pathogenesis of Polycystic Ovarian Syndrome. J Clin Endocrinol Metab 1993; 76: 1295-1300.

  34. Patel K, Coffler MS, Dahan MH, et al. Increased Luteinizing Hormone Secretion in Women with Polycystic Ovary Syndrome Is Unaltered by Prolonged Insulin Infusion. J Clin Endocrinol Metab 2003; 88:5456-1.

  35. Hogeveen KN, Cousin P, Pugeat M, et al. Human sex hormone-binding globulin variants associated with hyperandrogenism and ovarian dysfunction. J Clin Investigation 2002; 109: 973-81.

  36. Krentz, Andrew J, Insulin Resistance A Clinical Handbook. Blackwell Science 2002, Oxford, UK.

  37. Fitzpatrick TB, Johnson RA, Wolff K. Color Atlas and Synopsis of Clinical Dermatology - Common and Serious Diseases. 1997, 3rd Edition, McGraw-Hill, US.

  38. Garafalo L, Boscozzi AM, Mastrandea V, Bonifazi E. Acantosis nigricans vulgare: un indicatori di iperinsulinemia. Eur J Pediat Dermatol 2000; 13: 85-8.

  39. Franks, Stephen, et al. Nutrition, insulin and Polycystic Ovary Syndrome. Rev Reproduction 1996; 1: 47-53.

  40. Poy M, Wiltgen D, Spritzer PM, Perfil Hormonal e Metabólico em Pacientes Hirsutas com a Síndrome dos Ovários Policísticos. Arq Bras Endocrinol Metab 2001; 45: 352-60.

  41. Ralf P, Cotsarelis G. The biology of Hair Follicles. N England J Medicine 1999; 341:491-7.

  42. Azziz R. The Evaluation and Management of Hirsutism. Obstet Gynecol 2003; 101: 995-1007.

  43. Ferriman D, Gallwey JD. Clinical Assessment of body hair growth in women. J Clin Endocrinol Metabol 1961; 21: 1440-7.

  44. Hunter MH, Carek PJ. Evaluation and Treatment of Women with Hirsutism Am Fam Phycisian 2003; 67: 2565-72.

  45. Bershad SV. The Modern Age of Acne Therapy: A Review of Current Treatment Options. Mount Sinai J Medicine 2001; 68: 279-286.

  46. Faure M. Acné et hormones. Rev Prat 2002; 52: 850-3.

  47. Tan JKL, Vasey K, Fung KY. Attitudes of female Patients regarding Oral Contraceptives for Acne Treatment. J Cutan Med Surg 2001: 471-4.

  48. Seaman HE, Vries CS, Farmer RDT. Differences in the use of combined oral contraceptives amongst women with and without acne. Hum Reprod 2003; 18: 515-21.

  49. Krowchuk DP. Treating Acne. Med Clin North Am - Adolescent medicine 2000; 8:811-24.

  50. Wolf Jr JE. Maintenance Therapy for Acne Vulgaris: The Fine Balance Between Efficacy, Cutaneous Tolerability, and Adherence. SKINmed 2004, 3: 23-6.

  51. Ludwig E. Classification of the types of androgenetic alopecia occuring in the female sex. Br J Dermatol 1977; 97: 247-54.

  52. Price V. Treating Hair Loss. N England J Medicine 1999; 341: 964-73.

  53. Bonet Serra B, Sanchéz-Vera I, Cocho Gómez P, et al. Alteraciones relacionadas com el síndrome X y bajos níveles de vitamina E en niños con obesidad y acantosis nigricans. An Pediatr (Barc) 2004; 60: 142-7.

  54. Spritzer, Poli Mara, Revisitando o Hirsutismo. Arq Bras Endocrinol Metab 2002; 46: 127-36.

  55. Marx Theresa L, Mehta, Adi E. Polycystic ovary syndrome: Pathogenesis and treatmentover the short and long term. Cleveland Clin J Med 2003; 70: 31-45.

  56. Barbieri RL: The role of adipose tissue and hyperinsulinemia in the development of hyperandrogenism in women. In L’Hermite ML (ed): Progress in Reproductive Biology and Medicine 1990. Basel, Switzerland, Karger.

  57. Ducluzeau PH, Cousin P, Malvoisin E, et al. Glucose-to-Insulin Ratio Rather than Sex Hormone-Binding Globulin and Adiponectin Levels Is the Best Predictor of Insulin Resistance in Nonobese Women with Polycystic Ovary Syndrome. J Clin Endocrinol Metab 2003; 88: 3626-31.

  58. Legro R, Finegood D, Dunaif A. A Fasting Glucose to Insulin Ratio Is a Useful Measure of Insulin Sensitivity in Women with Polycystic Ovary Syndrome. J Clin Endocrinol Metab 1998; 83: 2694-8.

  59. Valmore Bermúdez P, et al. Homeostasis Model Assessment (HOMA) en Pacientes Diabéticos Tipo 2. Med Intern (Caracas) 2000; 16.

  60. Rajkhowa M, Neary RH, Kumpatla P, et al. Altered Composition of High Density Lipoproteins in Women with the Polycystic Ovary Syndrome. J Clin Endocrinol Metab 1997; 82: 3389-94.

  61. Pirwany IR, Fleming R, Greer IA, et al. Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters. Clin Endocrinol 2001; 54: 447-53.

  62. Healy E, Simpson N. Fortnightly Review Acne vulgaris. Br Med J 1994; 308: 831-3.

  63. Bunliffe B. Diseases of the skin and their tratment - Acne. The Pharmaceutical J 2001; 267: 749-52.

  64. Goldberg DJ. Laser hair Removal. Dermatol Clin 2002; 20: 561-7.

  65. Limmer BL. The density issue in hair transplantation. Dermatol Surg 1997; 23:747-50.

  66. Unger WP, David LM. Laser hair transplantation. J Dermatol Surg Oncol 1994; 20: 515-21.

  67. Avram M. Hair transplantation in women. Seminar Cutan Med Surg 1998; 18: 172-6.




2020     |     www.medigraphic.com